Fig. 3
Dose-response of HDAC inhibitors assessed in Mtb-infected host cells. Intracellular growth of H37Rv-GFP inside (A-B) macrophages or, (C-D) bulk PBMCs at the indicated concentrations of HDAC inhibitor compounds. Efficacy of selected compounds to reduce intracellular growth of H37Ra-GFP inside hMDMs (%) including (E) tenovin, (F) suramin, (G) salermide, (H) cambinol, (I) selisistat, (J) romidepsin, and assessment of macrophage viability (%) including (K) tenovin, (L) suramin, (M) salermide, (N) cambinol, (O) selisistat, (P) romidepsin. Data assessed with IncuCyte at day 3 is presented in individual dot plot graphs or bar graphs (median or, median and range) from n = 12 (A-D), or n = 3 (E-P) donors. Data in (E-P) was analyzed using a paired Friedman test and one out of three similar experiments are shown. The horizontal dotted lines indicate 100% and 50% intracellular Mtb growth in hMDM or PBMCs, respectively, while the vertical dotted lines (A-D) distinguish the selected sirtuin inhibitors (thick line) as well as the seven compounds (fade line) that inhibited intracellular Mtb growth in hMDMs ≥ 50% at a concentration of 1 µM. *P < 0.05, **P < 0.01, ***P < 0.001.
